2 FTSE 100 dividend stocks I’d buy in May

Roland Head highlights two stocks with the potential for long-term income growth.

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

Sales fell by 12% to $5,405m during the first quarter at pharmaceutical giant AstraZeneca (LSE: AZN). But shareholders are focused on the long-term potential of the group’s pipeline, which has been rejuvenated since chief executive Pascal Soriot took charge in October 2012.

Mr Soriot has previously promised that 2017 could be a defining year and recent news on new product development has started to provide some support for this claim.

In recent weeks, AstraZeneca has received full approvals in the US and Europe for its Tagrisso lung cancer medicine and has also launched the product in China. Sales of the group’s Lynparza medicine for ovarian and breast cancer rose by 30% to $57m during the quarter and have generated “positive data” so far.

New products like these form the basis of AstraZeneca’s valuation, which is very much based on the expected future value of its pipeline. I suspect this long-term view will pay off for patient shareholders.

Is it safe to wait?

AstraZeneca’s reported operating profit fell by 12% to $917m during the first quarter, due mainly to a loss of patent protection for the group’s Crestor medicine. Mr Soriot expects performance to stabilise during the second half of the year, but AstraZeneca’s core earnings per share are still expected to fall by “a low to mid-teens percentage” in 2017.

Buying a stock in the hope that future trading performance will improve always carries some risk. But opportunities such as these can be very profitable. In this case, I think it’s credible to believe that AstraZeneca will deliver significant growth from new products over the coming years.

For long-term investors, I think AstraZeneca’s forecast P/E of 16 and 4.5% dividend yield remain a decent entry point to this business.

Is this stock about to bounce back?

Shares of engineering support services company Babcock International Group (LSE: BAB) are down by 38% from their 2014 peak of nearly 1,500p. But the group’s performance has held up better than many of its outsourcing peers over the last couple of years.

There are several reasons for this. But in my view, the main advantages Babcock holds are that much of its work is highly skilled and in the public sector, principally defence. The barriers to entry for potential competitors are much higher than they are for security guards or cleaners, for example.

I’m beginning to think that Babcock stock could offer a buying opportunity for contrarian investors. The group’s third-quarter statement confirmed that full-year results ended on 31 March should be in line with expectations.

That puts Babcock on a forecast P/E of 11.5, falling to a P/E of 10.7 in 2017/18. The group’s dividend is expected to rise by 8% to 27.9p for 2016/17, giving a forecast yield of 3.0%. Although this is slightly below the FTSE 100 average, Babcock’s dividend has risen every year since at least 1998, so it could be worth accepting a slightly lower yield.

The group’s full-year results are due on 24 May, so we’ll learn more then. But in my view, Babcock International could be worth considering as a long-term buy.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Roland Head has no position in any shares mentioned. The Motley Fool UK has recommended AstraZeneca. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Investing Articles

Could the JD Sports Fashion share price double in the next five years?

The JD Sports Fashion share price has nearly halved in the past five years. Our writer thinks a proven business…

Read more »

Bus waiting in front of the London Stock Exchange on a sunny day.
Investing Articles

If interest rate cuts are coming, I think these UK growth stocks could soar!

Falling interest could be great news for UK growth stocks, especially those that have been under the cosh recently. Paul…

Read more »

Investing Articles

Are these the best stocks to buy on the FTSE right now?

With the UK stock market on the way to hitting new highs, this Fool is considering which are the best…

Read more »

Petrochemical engineer working at night with digital tablet inside oil and gas refinery plant
Investing Articles

Can the Centrica dividend keep on growing?

Christopher Ruane considers some positive factors that might see continued growth in the Centrica dividend -- as well as some…

Read more »

Smiling family of four enjoying breakfast at sunrise while camping
Investing Articles

How I’d turn my £12,000 of savings into passive income of £1,275 a month

This Fool is considering a strategy that he believes can help him achieve a stable passive income stream with a…

Read more »

Person holding magnifying glass over important document, reading the small print
Investing Articles

2 top FTSE 250 investment trusts trading at attractive discounts!

This pair of discounted FTSE 250 trusts appear to be on sale right now. Here's why I'd scoop up their…

Read more »

Smiling young man sitting in cafe and checking messages, with his laptop in front of him.
Investing Articles

3 things that could push the Lloyds share price to 60p and beyond

The Lloyds share price has broken through 50p. Next step 60p? And then what? Here are some thoughts on what…

Read more »

Young female business analyst looking at a graph chart while working from home
Investing Articles

£1,000 in Rolls-Royce shares a year ago would be worth this much now

Rolls-Royce shares have posted one of the best stock market gains of the past 12 months. But what might the…

Read more »